These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 24200969)

  • 1. Activities of multiple cancer-related pathways are associated with BRAF mutation and predict the resistance to BRAF/MEK inhibitors in melanoma cells.
    Liu D; Liu X; Xing M
    Cell Cycle; 2014; 13(2):208-19. PubMed ID: 24200969
    [TBL] [Abstract][Full Text] [Related]  

  • 2. BRAF- and MEK-Targeted Small Molecule Inhibitors Exert Enhanced Antimelanoma Effects in Combination With Oncolytic Reovirus Through ER Stress.
    Roulstone V; Pedersen M; Kyula J; Mansfield D; Khan AA; McEntee G; Wilkinson M; Karapanagiotou E; Coffey M; Marais R; Jebar A; Errington-Mais F; Melcher A; Vile R; Pandha H; McLaughlin M; Harrington KJ
    Mol Ther; 2015 May; 23(5):931-942. PubMed ID: 25619724
    [TBL] [Abstract][Full Text] [Related]  

  • 3. COT drives resistance to RAF inhibition through MAP kinase pathway reactivation.
    Johannessen CM; Boehm JS; Kim SY; Thomas SR; Wardwell L; Johnson LA; Emery CM; Stransky N; Cogdill AP; Barretina J; Caponigro G; Hieronymus H; Murray RR; Salehi-Ashtiani K; Hill DE; Vidal M; Zhao JJ; Yang X; Alkan O; Kim S; Harris JL; Wilson CJ; Myer VE; Finan PM; Root DE; Roberts TM; Golub T; Flaherty KT; Dummer R; Weber BL; Sellers WR; Schlegel R; Wargo JA; Hahn WC; Garraway LA
    Nature; 2010 Dec; 468(7326):968-72. PubMed ID: 21107320
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PI3'-kinase inhibition forestalls the onset of MEK1/2 inhibitor resistance in BRAF-mutated melanoma.
    Deuker MM; Marsh Durban V; Phillips WA; McMahon M
    Cancer Discov; 2015 Feb; 5(2):143-53. PubMed ID: 25472943
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of HSP90 by AT13387 delays the emergence of resistance to BRAF inhibitors and overcomes resistance to dual BRAF and MEK inhibition in melanoma models.
    Smyth T; Paraiso KHT; Hearn K; Rodriguez-Lopez AM; Munck JM; Haarberg HE; Sondak VK; Thompson NT; Azab M; Lyons JF; Smalley KSM; Wallis NG
    Mol Cancer Ther; 2014 Dec; 13(12):2793-2804. PubMed ID: 25349308
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exploiting Allosteric Properties of RAF and MEK Inhibitors to Target Therapy-Resistant Tumors Driven by Oncogenic BRAF Signaling.
    Adamopoulos C; Ahmed TA; Tucker MR; Ung PMU; Xiao M; Karoulia Z; Amabile A; Wu X; Aaronson SA; Ang C; Rebecca VW; Brown BD; Schlessinger A; Herlyn M; Wang Q; Shaw DE; Poulikakos PI
    Cancer Discov; 2021 Jul; 11(7):1716-1735. PubMed ID: 33568355
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor cell sensitivity to vemurafenib can be predicted from protein expression in a BRAF-V600E basket trial setting.
    Carroll MJ; Parent CR; Page D; Kreeger PK
    BMC Cancer; 2019 Oct; 19(1):1025. PubMed ID: 31672130
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Predictive Model of Adaptive Resistance to BRAF/MEK Inhibitors in Melanoma.
    Ruiz EM; Alhassan SA; Errami Y; Abd Elmageed ZY; Fang JS; Wang G; Brooks MA; Abi-Rached JA; Kandil E; Zerfaoui M
    Int J Mol Sci; 2023 May; 24(9):. PubMed ID: 37176114
    [TBL] [Abstract][Full Text] [Related]  

  • 9. RICTOR/mTORC2 downregulation in BRAF
    Ponzone L; Audrito V; Landi C; Moiso E; Levra Levron C; Ferrua S; Savino A; Vitale N; Gasparrini M; Avalle L; Vantaggiato L; Shaba E; Tassone B; Saoncella S; Orso F; Viavattene D; Marina E; Fiorilla I; Burrone G; Abili Y; Altruda F; Bini L; Deaglio S; Defilippi P; Menga A; Poli V; Porporato PE; Provero P; Raffaelli N; Riganti C; Taverna D; Cavallo F; Calautti E
    Mol Cancer; 2024 May; 23(1):105. PubMed ID: 38755661
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of Stearoyl-CoA desaturase 1 reverts BRAF and MEK inhibition-induced selection of cancer stem cells in BRAF-mutated melanoma.
    Pisanu ME; Maugeri-Saccà M; Fattore L; Bruschini S; De Vitis C; Tabbì E; Bellei B; Migliano E; Kovacs D; Camera E; Picardo M; Jakopin Z; Cippitelli C; Bartolazzi A; Raffa S; Torrisi MR; Fulciniti F; Ascierto PA; Ciliberto G; Mancini R
    J Exp Clin Cancer Res; 2018 Dec; 37(1):318. PubMed ID: 30558661
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of ABT-888 on the apoptosis, motility and invasiveness of BRAFi-resistant melanoma cells.
    Fratangelo F; Camerlingo R; Carriero MV; Pirozzi G; Palmieri G; Gentilcore G; Ragone C; Minopoli M; Ascierto PA; Motti ML
    Int J Oncol; 2018 Sep; 53(3):1149-1159. PubMed ID: 29956724
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II trial of MEK inhibitor selumetinib (AZD6244, ARRY-142886) in patients with BRAFV600E/K-mutated melanoma.
    Catalanotti F; Solit DB; Pulitzer MP; Berger MF; Scott SN; Iyriboz T; Lacouture ME; Panageas KS; Wolchok JD; Carvajal RD; Schwartz GK; Rosen N; Chapman PB
    Clin Cancer Res; 2013 Apr; 19(8):2257-64. PubMed ID: 23444215
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An NKX2-1/ERK/WNT feedback loop modulates gastric identity and response to targeted therapy in lung adenocarcinoma.
    Zewdu R; Mehrabad EM; Ingram K; Fang P; Gillis KL; Camolotto SA; Orstad G; Jones A; Mendoza MC; Spike BT; Snyder EL
    Elife; 2021 Apr; 10():. PubMed ID: 33821796
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CRAF inhibition induces apoptosis in melanoma cells with non-V600E BRAF mutations.
    Smalley KS; Xiao M; Villanueva J; Nguyen TK; Flaherty KT; Letrero R; Van Belle P; Elder DE; Wang Y; Nathanson KL; Herlyn M
    Oncogene; 2009 Jan; 28(1):85-94. PubMed ID: 18794803
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BRAF inhibitors promote intermediate BRAF(V600E) conformations and binary interactions with activated RAS.
    Röck R; Mayrhofer JE; Torres-Quesada O; Enzler F; Raffeiner A; Raffeiner P; Feichtner A; Huber RG; Koide S; Taylor SS; Troppmair J; Stefan E
    Sci Adv; 2019 Aug; 5(8):eaav8463. PubMed ID: 31453322
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quantitative Proteomics Links the Intermediate Filament Nestin to Resistance to Targeted BRAF Inhibition in Melanoma Cells.
    Schmitt M; Sinnberg T; Nalpas NC; Maass A; Schittek B; Macek B
    Mol Cell Proteomics; 2019 Jun; 18(6):1096-1109. PubMed ID: 30890564
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Whole-genome sequencing reveals complex mechanisms of intrinsic resistance to BRAF inhibition.
    Turajlic S; Furney SJ; Stamp G; Rana S; Ricken G; Oduko Y; Saturno G; Springer C; Hayes A; Gore M; Larkin J; Marais R
    Ann Oncol; 2014 May; 25(5):959-67. PubMed ID: 24504448
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MEK1 mutations confer resistance to MEK and B-RAF inhibition.
    Emery CM; Vijayendran KG; Zipser MC; Sawyer AM; Niu L; Kim JJ; Hatton C; Chopra R; Oberholzer PA; Karpova MB; MacConaill LE; Zhang J; Gray NS; Sellers WR; Dummer R; Garraway LA
    Proc Natl Acad Sci U S A; 2009 Dec; 106(48):20411-6. PubMed ID: 19915144
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Paradox-breaking RAF inhibitors that also target SRC are effective in drug-resistant BRAF mutant melanoma.
    Girotti MR; Lopes F; Preece N; Niculescu-Duvaz D; Zambon A; Davies L; Whittaker S; Saturno G; Viros A; Pedersen M; Suijkerbuijk BM; Menard D; McLeary R; Johnson L; Fish L; Ejiama S; Sanchez-Laorden B; Hohloch J; Carragher N; Macleod K; Ashton G; Marusiak AA; Fusi A; Brognard J; Frame M; Lorigan P; Marais R; Springer C
    Cancer Cell; 2015 Jan; 27(1):85-96. PubMed ID: 25500121
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Proteasome inhibition potentiates Kv1.3 potassium channel expression as therapeutic target in drug-sensitive and -resistant human melanoma cells.
    Cammann C; Kulla J; Wiebusch L; Walz C; Zhao F; Lowinus T; Topfstedt E; Mishra N; Henklein P; Bommhardt U; Bossaller L; Hagemeier C; Schadendorf D; Schmidt B; Paschen A; Seifert U
    Biomed Pharmacother; 2023 Dec; 168():115635. PubMed ID: 37816303
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.